AMD3100: A Versatile Platform for CXCR4 Targeting (68)Ga-Based Radiopharmaceuticals

Area of Science:

• Radiochemistry
• Molecular Imaging
• Oncology

Background:

• CXCR4 receptor is overexpressed in many cancers, making it a target for imaging and therapy.
• Existing CXCR4 imaging agents using AMD3100 have limitations due to chelator issues, potentially causing in vivo radionuclide release.
• There is a need for novel, stable imaging agents for accurate CXCR4 detection.

Purpose of the Study:

• To develop and evaluate a new family of CXCR4-targeting imaging agents for Positron Emission Tomography (PET).
• To functionalize AMD3100 with different linkers and chelators for improved Gallium-68 (68Ga) complexation.
• To assess the in vitro and in vivo performance of novel CXCR4-targeting agents.

Main Methods:

• AMD3100 was modified with ethylenediamine or PEG3 linkers and coupled with DOTA or NODAGA chelators.
• The resulting ligands were radiolabeled with 68Ga, and labeling yields were analyzed.
• Lipophilicity, CXCR4 receptor affinity, and in vivo biodistribution/PET imaging in H69 tumor xenografts were evaluated.

Main Results:

• Five novel AMD3100-based ligands were synthesized and successfully labeled with 68Ga.
• Spacer type influenced 68Ga labeling efficiency.
• The most promising agent demonstrated favorable lipophilicity, high affinity, and effective tumor uptake in preclinical models.

Conclusions:

• Novel AMD3100-based 68Ga imaging agents targeting CXCR4 were successfully developed.
• These agents show potential for improved PET imaging of CXCR4-expressing cancers.
• The study validates the concept of using AMD3100 as a carrier for targeted PET imaging agents.